Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors

BACKGROUND: The objective of this study was to report on the long‐term effects of pexidartinib on tenosynovial giant cell tumor (TGCT). METHODS: This was a pooled analysis encompassing 3 pexidartinib‐treated TGCT cohorts: 1) a phase 1 extension study (NCT01004861; 1000 mg/d; n = 39), 2) ENLIVEN pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelderblom, Hans, Wagner, Andrew J., Tap, William D., Palmerini, Emanuela, Wainberg, Zev A., Desai, Jayesh, Healey, John H., van de Sande, Michiel A. J., Bernthal, Nicholas M., Staals, Eric L., Peterfy, Charles G., Frezza, Anna Maria, Hsu, Henry H., Wang, Qiang, Shuster, Dale E., Stacchiotti, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946703/
https://www.ncbi.nlm.nih.gov/pubmed/33197285
http://dx.doi.org/10.1002/cncr.33312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946703/
https://www.ncbi.nlm.nih.gov/pubmed/33197285
http://dx.doi.org/10.1002/cncr.33312

Ejemplares similares